Population
Patients with neuroleptic malignant syndrome or Parkinson's disease after withdrawal of antiparkinsonian…
Design
Guideline
Key result
Dopamine agonists such as bromocriptine and the direct-acting muscle relaxant dantrolene have been used with good clinical outcomes in the treatment of neuroleptic malignant syndrome.
Authors
Loading...
Provides clinical guidelines for the treatment of neuroleptic malignant syndrome and the safe reinstitution of neuroleptic medications.
Provides clinical guidelines for the treatment of neuroleptic malignant syndrome and the safe reinstitution of neuroleptic medications.
Thomas R. Olmsted (1988) conducted a review in Neuroleptic Malignant Syndrome. Dopamine agonists (e.g., bromocriptine) and dantrolene was evaluated. Dopamine agonists such as bromocriptine and the direct-acting muscle relaxant dantrolene have been used with good clinical outcomes in the treatment of neuroleptic malignant syndrome.